• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

360
65
47
45
21

COUNTRY

44
12
6
5
5

PRICE

209
454
669
1,258

PUBLISHED

44
137
401
1,258

PRODUCT TYPE

1,226
17
11
4

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Equine Encephalitis - Pipeline Review, H1 2014

Equine Encephalitis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Equine Encephalitis - Pipeline Review, H1 2014’, provides an overview of the Equine Encephalitis’s therapeutic pipeline. This...

February 2014
FROM

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its...

February 2014
FROM

Substance (Drug) Abuse - Pipeline Review, H1 2014

Substance (Drug) Abuse - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Substance (Drug) Abuse - Pipeline Review, H1 2014’, provides an overview of the Substance (Drug) Abuse’s therapeutic...

February 2014
FROM

Drug Addiction - Pipeline Review, H1 2014

Drug Addiction - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Drug Addiction - Pipeline Review, H1 2014’, provides an overview of the Drug Addiction’s therapeutic pipeline. This report...

February 2014
FROM

Acute Pain - Pipeline Review, H1 2014

Acute Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H1 2014’, provides an overview of the Acute Pain’s therapeutic pipeline. This report provides...

February 2014
FROM

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core...

February 2014
FROM

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its...

February 2014
FROM

Epilepsy - Pipeline Review, H1 2014

Epilepsy - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H1 2014’, provides an overview of the Epilepsy’s therapeutic pipeline. This report provides comprehensive...

February 2014
FROM

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as one...

February 2014
FROM

EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023 Summary Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following...

February 2014
FROM

Mental Health and Work: United Kingdom

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

February 2014
FROM

Batten Disease - Pipeline Review, H1 2014

Batten Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Batten Disease - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides...

January 2014
FROM

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic...

January 2014
FROM

Mental Health and Work: Switzerland

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

January 2014
FROM

General Anxiety Disorder - Pipeline Review, H2 2013

General Anxiety Disorder - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'General Anxiety Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review,...

December 2013
FROM
Loading Indicator

Our Clients

Our clients' logos